Divi's Laboratories (DIVISLAB) | Stock Overview & Key Data
Divi's Laboratories Performance Comparison
Stock Range
Today's Range
Low: ₹6,008.50
High: ₹6,124.50
on September 23, 2025
52 Week Range
Low: ₹4,955.00
High: ₹7,071.50
on April 7, 2025
on July 8, 2025
All-Time High: ₹7,071.50 on July 8, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR1.6T
EPS
87.12
P/E Ratio (TTM)
69.93
Forward P/E
108.21
P/B Ratio
10.80
PEG Ratio
2.64
Div. Yield
0.91%
ROE
14.64%
Beta
0.234
Debt to Equity
0.03
Financial Highlights
Profitability
Gross Margin
60.33%
Operating Margin
25.60%
Profit Margin
23.89%
Returns and Earnings
Return on Assets (TTM)
12.94%
Return on Equity (TTM)
14.64%
EBITDA
INR34.7B
Net Income (TTM)
INR23.1B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR363.58
Quarterly Revenue Growth (YoY)
13.80%
Quarterly Earnings Growth (YoY)
26.70%
Dividend Information
Last 12-Month Dividend
₹60.00
Current Dividend Yield
0.91%
3-Year Average Dividend Yield
0.70%
3-Year Average Annual Dividend
₹50.00
3-Year Total Dividends
₹150.00
Ex-Dividend Date
July 25, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | 0.59% | -0.96% | -8.19% | 3.08% | 0.32% | 11.63% | 64.43% | 98.78% |
| Sun Pharmaceutical SUNPHARMA | 3.94T Large-cap | 2.62% | 0.13% | -1.11% | -7.89% | -13.01% | -15.64% | 73.30% | 224.32% |
| Cipla CIPLA | 1.24T Large-cap | -0.39% | -3.18% | 3.08% | 1.19% | 4.24% | 7.13% | 38.32% | 99.51% |
| Torrent TORNTPHARM | 1.21T Large-cap | 3.52% | -0.80% | 15.49% | 11.75% | 6.94% | 4.98% | 134.38% | 29.77% |
| Dr. Reddy's DRREDDY | 1.11T Large-cap | 0.05% | 1.86% | -1.25% | 7.53% | -4.94% | -3.60% | 50.08% | 27.29% |
| Mankind Pharma MANKIND | 1.06T Large-cap | 0.37% | -0.46% | 12.79% | 9.39% | -9.93% | 0.11% | 86.09% | 86.09% |
Ownership & Short Interest
Insider Ownership
52.10%
Institutional Ownership
28.98%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
417K
Average 90-Day Volume
389K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is DIVISLAB's 52-week high and low?
- In the last 52 weeks, Divi's Laboratories reached a high of ₹7,071.50 (on July 8, 2025) and a low of ₹4,955.00 (on April 7, 2025).
- What is the market cap and P/E ratio for DIVISLAB?
- Curious about Divi's Laboratories's size and valuation? Its market capitalization stands at 1.63T. When it comes to valuation, the P/E ratio (trailing twelve months) is 69.93, and the forward P/E (looking ahead) is 108.21.
- Does DIVISLAB pay dividends? If so, what's the yield?
- Yes, Divi's Laboratories is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.91%, and the company has paid an average of ₹50.00 per share annually over the past 3 years.
- Who are Divi's Laboratories's main competitors or similar companies to consider before investing?
When looking at Divi's Laboratories, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.94T Healthcare Drug Manufacturers - Specialty & Generic -15.64% 73.30% Cipla
CIPLA1.24T Healthcare Drug Manufacturers - Specialty & Generic 7.13% 38.32% Torrent
TORNTPHARM1.21T Healthcare Drug Manufacturers - Specialty & Generic 4.98% 134.38% Dr. Reddy's
DRREDDY1.11T Healthcare Drug Manufacturers - Specialty & Generic -3.60% 50.08% Mankind Pharma
MANKIND1.06T Healthcare Drug Manufacturers - Specialty & Generic 0.11% 86.09% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Divi's Laboratories Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Divi's Laboratories's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 14.64%, the Debt to Equity ratio from the most recent quarter is 0.03, and its Gross Profit Margin stands at 60.33%.
- What is the recent revenue and earnings growth for DIVISLAB?
- Looking at Divi's Laboratories's growth, its revenue over the trailing twelve months (TTM) was INR97B. Compared to the same quarter last year (YoY), quarterly revenue grew by 13.80%, and quarterly earnings saw a YoY growth of 26.70%.
- How much of DIVISLAB stock is held by insiders and institutions?
- Wondering who owns Divi's Laboratories stock? Company insiders (like executives and directors) hold about 52.10% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 28.98%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.